van Gils, N 2022, ' Therapeutic target identification and drug-target validation for acute myeloid leukemia ', Doctor of Philosophy, Vrije Universiteit Amsterdam, Leiden . < https://hdl.handle.net/1871.1/42db4527-8009-406a-9069-bf0871c991c8 > van Gils, N 2022, ' Therapeutic target identification and drug-target validation for acute myeloid leukemia ', PhD, Vrije Universiteit Amsterdam, Leiden .
Leukemia, 1751-1759. Nature Publishing Group ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia Leukemia, 34(7), 1751-1759. Nature Publishing Group Leukemia, 34, 7, pp. 1751-1759 Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0 Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP Leukemia, 34, 1751-1759 Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)